Clinical Trial: Safety and Efficacy of FTY720 in Adult Patients who Receive a Kidney Transplant

This study is currently recruiting patients.

Sponsored by: Novartis Pharmaceuticals
Information provided by: Novartis Pharmaceuticals

Purpose

The safety and efficacy of FTY720 is being evaluated in patients who receive a kidney transplant.

Condition Treatment or Intervention Phase
Kidney Transplantation
 Drug: FTY720
Phase III

MedlinePlus consumer health information 

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study

Further Study Details: 

Study start: December 2004

Eligibility

Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

  • Patients undergoing their first kidney transplant
  • Male or female age 18 to 65 years

Exclusion Criteria:

  • Patients in need of second kidney transplant or multi-organ transplants.

Location and Contact Information


Alabama
      The University of Alabama (Birmingham), Birmingham,  Alabama,  35294,  United States; Recruiting
Patsy Jones, RN  205-934-1389    patsyj@uab.edu 
Carlton Young, MD,  Principal Investigator

Missouri
      Washington University (St. Louis)/Barnes Jewish Hospital, St. Louis,  Missouri,  63110,  United States; Recruiting
Mark Lockwood  314-362-4109    lockwoodm@msnotes.wustl.edu 
Kim Knolhoff  314-362-8351    knolhoffk@msnotes.wustl.edu 
Daniel C Brennan, MD,  Principal Investigator

Ohio
      Ohio State University College of Medicine (OSU), Columbus,  Ohio,  43210,  United States; Recruiting
Jill Baxa  614-293-5414    baxa-1@medctr.osu.edu 
Tomasina Wall  614-293-8195    wall-2@medctr.osu.edu 
Ronald M Ferguson, MD,  Principal Investigator

Oregon
      Oregon Health Sciences University School of Medicine (OHSU)/Oregon Health Sciences University Hospital, Portland,  Oregon,  97239,  United States; Not yet recruiting
Ted Norton  503-494-8976    nortont@ohsu.edu 
Tammy LaBeck  503-494-6893    labeckt@ohsu.edu 
Muralikrishna Golconda, MD,  Principal Investigator

More Information

Study ID Numbers:  CFTY720A2307
Record last reviewed:  December 2004
Last Updated:  December 20, 2004
Record first received:  December 20, 2004
ClinicalTrials.gov Identifier:  NCT00099801
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Resources